Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
VivoSim Labs operates as a pre-revenue biotechnology company developing simulation-based medical training platforms and potentially therapeutic solutions. The company exhibits classic early-stage biotech characteristics with 96.5% gross margins indicating minimal cost of goods sold, negative operating cash flow of approximately $0.0B, and a 3.10x current ratio suggesting adequate near-term liquidity to fund operations. The stock trades at 35.8x sales despite minimal revenue, reflecting speculative valuation on future commercialization potential.
VivoSim Labs appears to generate minimal revenue from early-stage product sales or pilot programs in medical simulation technology. The 96.5% gross margin indicates a software-centric or IP-licensing model with negligible manufacturing costs. The -8761% operating margin reflects heavy R&D and commercialization investments typical of pre-revenue biotech, with operating expenses vastly exceeding current revenue. The company likely relies on equity financing (evidenced by low 0.10x debt/equity) to fund product development, clinical validation studies, and market entry efforts. Pricing power remains unproven until commercial-scale adoption occurs.
Product development milestones including FDA clearances, CE marks, or clinical validation study results for simulation platforms
Commercial partnership announcements with major hospital systems, medical schools, or healthcare networks
Quarterly revenue growth rates and customer acquisition metrics (active installations, recurring revenue conversion)
Cash runway updates and financing events given negative operating cash flow and pre-profitability status
Competitive positioning announcements versus established medical simulation providers (CAE Healthcare, Laerdal Medical)
Regulatory pathway uncertainty for medical simulation devices requiring FDA clearance or international equivalents, with approval timelines extending 18-36 months and creating commercialization delays
Rapid technological obsolescence risk as virtual reality, augmented reality, and AI-driven simulation platforms evolve quickly, requiring continuous R&D investment to maintain competitive positioning
Reimbursement and adoption barriers as healthcare institutions face budget constraints and require clinical evidence demonstrating improved patient outcomes or cost savings to justify capital expenditures
Market concentration risk with limited number of large hospital systems and medical schools representing majority of addressable market, creating customer concentration vulnerability
Established medical simulation incumbents (CAE Healthcare, Laerdal Medical, Gaumard Scientific) possess existing customer relationships, regulatory clearances, and distribution networks creating high barriers to market entry
Large medical device companies (Medtronic, Stryker) could enter simulation market through acquisition or internal development, leveraging existing hospital relationships and capital resources
Open-source and low-cost simulation alternatives emerging from academic institutions potentially commoditizing basic training applications
Customer switching costs may be lower than anticipated if simulation platforms lack proprietary data or integration with hospital IT systems
Cash runway risk with -$0.0B operating cash flow requiring continuous equity financing; at current burn rate, the 3.10x current ratio suggests 9-15 months of liquidity assuming $2-4M quarterly cash consumption
Equity dilution risk from future financing rounds given pre-revenue status and 0.10x debt/equity indicating limited debt capacity; existing shareholders face 30-50% dilution risk in next 12-18 months
Working capital volatility as customer payment terms in healthcare typically extend 60-90 days, creating cash conversion cycle pressure during revenue ramp
Contingent liabilities from potential licensing agreements, clinical trial obligations, or regulatory compliance requirements not fully reflected in current financial statements
moderate - Healthcare technology spending exhibits defensive characteristics but capital equipment purchases by hospitals and medical schools correlate with institutional budgets, which compress during recessions. The company's pre-revenue status makes it more sensitive to venture capital availability and risk appetite than established healthcare firms. Medical education spending proves relatively stable, but discretionary simulation technology purchases may defer during economic stress. GDP growth below 2% typically pressures healthcare capital budgets.
High sensitivity through multiple channels: (1) Valuation compression as rising rates reduce present value of distant future cash flows, particularly severe for pre-revenue biotech trading at 35.8x sales; (2) Increased cost of capital for future financing rounds given 0.10x debt/equity suggests equity-dependent funding model; (3) Customer financing costs for capital equipment purchases rise with rates, potentially extending sales cycles. Federal funds rate above 4.5% historically correlates with 20-30% valuation compression for unprofitable growth companies. The -189.2% FCF yield makes the company highly vulnerable to rate-driven multiple contraction.
Minimal direct credit exposure given low 0.10x debt/equity ratio and apparent equity financing model. However, indirect exposure exists through: (1) Customer credit quality as hospital systems and medical schools face budget constraints during credit tightening; (2) Venture capital and growth equity availability for future funding rounds, which contracts when high-yield spreads exceed 500bps; (3) Potential acquisition currency if the company seeks strategic exit, as acquirer financing costs rise with credit spreads. The 3.10x current ratio provides near-term insulation from credit market disruptions.
growth - The stock attracts speculative growth investors and venture capital-style public market participants willing to accept extreme volatility and binary outcomes. The 35.8x price/sales multiple, -189.2% FCF yield, and pre-revenue status appeal to investors focused on total addressable market potential rather than current fundamentals. The 11.6% one-year return with -15.8% three-month drawdown indicates momentum-driven trading. Not suitable for value, income, or risk-averse investors given negative profitability, no dividend, and 0.4x price/book suggesting market skepticism about asset value.
high - Pre-revenue biotechnology stocks typically exhibit 60-100% annualized volatility with beta exceeding 2.0x. The -15.8% three-month decline followed by 11.6% one-year gain demonstrates significant price swings. Binary catalysts (regulatory approvals, partnership announcements, financing events) create 20-40% single-day moves. Low float and minimal institutional ownership likely amplify volatility. Options market activity and short interest would provide additional volatility indicators but are unavailable. Investors should expect drawdowns exceeding 50% during adverse developments or broader market corrections affecting unprofitable growth stocks.
